Half year report of pharmaceutical enterprises! The net profit of 11 medical device enterprises increased by 5 times

In the first half of 2020, the demand for medical materials such as masks, medical gloves, ventilators and so on increased sharply due to the new crown epidemic, which brought about a sharp increase in the performance of related enterprises. As of August 28, 306 pharmaceutical companies in a shares disclosed semi annual reports, of which 163 companies achieved year-on-year growth in net profit attributable to their parent companies, accounting for more than 50% of the total. < / P > < p > the medical device industry is undoubtedly a “black horse” in performance. Among the 306 pharmaceutical companies, the top 11 companies with the growth rate of net profit attributable to their parent companies all belong to the medical device industry, all of which exceed 500%. The performance of pharmaceutical stocks in the first half of this year has also become a bright spot. According to Oriental Wealth choice data, as of the morning closing, 30 pharmaceutical stocks have doubled this year (excluding the new shares listed this year). Among them, enko Medical Co., Ltd. won the top spot with an increase of 770.77%. As of August 28, 42 pharmaceutical companies had a year-on-year growth rate of more than 100%, according to Oriental Fortune choice. Among them, the top 11 companies belong to the medical device industry, and all of them are over 500%. Industrial medical ranked first with the growth rate of 2611.87%. In the first half of the year, the global demand for disposable protective gloves surged, and the price of disposable protective gloves increased significantly. At the same time, the company further reduced energy consumption, improved production efficiency, improved product quality, so that the company’s sales revenue and gross profit margin were increased during the reporting period. According to the semi annual report released by Zhende Medical Co., Ltd. on August 18, the company realized the main business income of 3.814 billion yuan, an increase of 404.78% over the same period of last year, and the net profit attributable to the owner of the parent company was 989 million yuan, an increase of 1544.74% over the same period of last year. < / P > < p > the company said that the substantial growth in performance was mainly due to the impact of the epidemic situation. The company’s sales of anti epidemic protection products and business scale increased significantly, which promoted the overall gross profit margin of the company’s products during the reporting period. At the same time, the acquisition of 55% equity of British rocialle healthcare limited company in the last year was included in the scope of the company’s consolidated statements, which also improved the company’s performance. < / P > < p > nucleic acid detection is of great significance for the detection of infected persons and the implementation of precise prevention and control. The substantial increase in demand has promoted the performance of relevant companies. The net profit growth rate of Oriental biology, Daan gene, shuoshi biology, Huada gene and other related companies are in the forefront. < / P > < p > in addition, some chemical pharmaceutical and CXO (pharmaceutical R & D and production outsourcing) sectors which were less affected by the epidemic situation maintained a high degree of prosperity and achieved growth. In terms of chemical medicine, the net profit of Haizheng pharmaceutical, Shengda biological, Yongan pharmaceutical, boten, Huaren pharmaceutical, shengjitang and Xingqi eye medicine in the first half of the year increased by more than 100%. In addition, the net profit of KANGLONG Huacheng and yaomingkant increased by 196.89% and 62.49% respectively in the first half of the year. < p > < p > even though affected by the epidemic situation, pharmaceutical enterprises are still increasing R & D investment. In terms of R & D expenses, in the first half of this year, Hengrui pharmaceutical, Fosun Pharmaceutical and Renfu pharmaceutical ranked among the top three, with 1.863 billion yuan, 1.204 billion yuan and 344 million yuan respectively. < p > < p > Hengrui pharmaceutical, which has a market value of more than 500 billion yuan, recently released a semi annual report. During the reporting period, the cumulative R & D investment increased by 25.56% year-on-year, accounting for 16.48% of the sales revenue, which strongly supported the company’s project R & D and innovation development. In the first half of this year, 50 pharmaceutical companies in the biomedical industry spent more than 100 million yuan on R & D, and 13 pharmaceutical companies accounted for more than 20% of their revenue in the first half of this year. According to the year-on-year growth rate of R & D expenses, 111 pharmaceutical enterprises have reported that their R & D expenses have increased by more than 20% year-on-year. Among them, Kanghua biological, Zhende medical and Yuyue medical R & D expenses ranked among the top three, with 226.39%, 224.7% and 218.55% respectively. Since the beginning of this year, China’s medical system reform has been pushed forward, such as the normalization of volume purchase, and the results of the third batch purchase have been announced recently. In addition, the National Medical Insurance Bureau issued the work plan for the adjustment of the national medical insurance drug catalog in 2020 and the Application guide for the adjustment of the national medical insurance drug catalog in 2020 on August 17. According to Wanhe securities, the scope of the list to be adjusted is not only included in the list of new drugs listed as of the date of announcement of the plan, the drugs urgently needed in clinical practice and the drugs jointly recognized by more than five provinces, but also the scope of drugs to be included in the adjusted medical insurance catalogue. After the reform of new drug evaluation and national centralized purchase, combined with the dynamic adjustment of medical insurance catalogue, a set of innovative combination boxing will be effectively formed to promote the supply side reform of the pharmaceutical industry. Domestic innovative drugs will usher in a golden development period, and the number of innovative drugs will usher in a new high. In the first half of this year, the year-on-year increase in the performance of anti epidemic related stocks also led to the bright performance of stock prices. According to Oriental Wealth choice data, as of the morning closing, 38 pharmaceutical companies had a stock increase of more than 100% (excluding the new shares listed this year). Among them, industrial medical Co., Ltd. gained the top position with an increase of 770.77%, with a market value of 32 billion yuan. In the first half of the year, the stock prices of shuoshi biological and Zhengchuan (specialized in the research and development, production and sales of pharmaceutical packaging materials such as glass tube bottles) were very good in the first half of the year. From the beginning of the year, the stock prices of shuoshi biological and Zhengchuan shares increased by 326.08% and 257.04% respectively. < p > < p > Caixin Securities believes that in the short term, the medium-term reports will be published intensively, and the performance of enterprises such as gloves, masks and IVD (in vitro diagnosis) will increase greatly; in terms of capital flow, pharmacies will pay more attention to it. < / P > < p > in the long run, policies such as centralized purchase and national health insurance catalog adjustment force pharmaceutical enterprises to carry out innovation and increase R & D. the domestic innovation boom will continue. Enterprises with R & D pipeline in the cash period will receive higher attention, and CXO enterprises will continue to benefit. < p > < p > recently, the stock price of pharmaceutical sector has been adjusted. Sichuan Financial Securities believes that after the previous plate adjustment, some stocks have returned to or lower than the reasonable valuation range. It is suggested that the low price distribution should be low value, and the stocks should be oriented to good stocks, especially medical devices, medical services and influenza vaccine with consumption attributes, and innovative medicine driven by the trend of volume procurement. < / P > < p > Disclaimer: the purpose of this article reprinted by china.com finance and economics is to convey more information and does not represent the views and positions of the website. The content of this paper is for reference only and does not constitute investment advice. Investors operate accordingly and bear their own risks. < p > < p > Chinanet is a national key news website under the leadership of the Information Office of the State Council and managed by China foreign language publishing and Distribution Bureau. Through 11 versions in 10 languages, the website releases information 24 hours a day, which is an important window for China to carry out international communication and information exchange.